These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results

Benzinga05-13

Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.

Liquidia reported quarterly earnings of 52 cents per share which beat the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $132.865 million which beat the analyst consensus estimate of $116.675 million.

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”

Liquidia shares gained 3.1% to trade at $54.80 on Tuesday.

These analysts made changes to their price targets on Liquidia following earnings announcement.

Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $51 to $62.
HC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $55 to $67.

Considering buying LQDA stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635241241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 02:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635241241","market":"hk","top_or_hot":-1,"title":"These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results","media":"Benzinga","content":"<html><body><p><strong>Liquidia Corp</strong> (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.</p>\n<p>Liquidia reported quarterly earnings of 52 cents per share which beat the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $132.865 million which beat the analyst consensus estimate of $116.675 million.</p>\n<p>Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”</p>\n<p>Liquidia shares gained 3.1% to trade at $54.80 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Liquidia following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $51 to $62.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $55 to $67.</li>\n</ul>\n<p><strong>Considering buying LQDA stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"450\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-1024x450.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-1024x450.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-300x132.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-768x338.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302.png 1221w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-05-13 02:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Liquidia Corp</strong> (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.</p>\n<p>Liquidia reported quarterly earnings of 52 cents per share which beat the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $132.865 million which beat the analyst consensus estimate of $116.675 million.</p>\n<p>Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”</p>\n<p>Liquidia shares gained 3.1% to trade at $54.80 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Liquidia following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $51 to $62.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $55 to $67.</li>\n</ul>\n<p><strong>Considering buying LQDA stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"450\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-1024x450.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-1024x450.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-300x132.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302-768x338.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/12140407/image-302.png 1221w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52500708/these-analysts-boost-their-forecasts-on-liquidia-after-upbeat-q1-results","article_id":"2635241241","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635241241","pubTimestamp":1778609181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Liquidia Corp (LQDA) reported better-than-expected Q1 results, with earnings of 52 cents per share and sales of $132.865 million. Analysts raised price targets on LQDA stock.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LQDA":"Liquidia Technologies Inc"},"translate_title":"在第一季度业绩乐观后，这些分析师上调了对Liquidia的预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.\nLiquidia reported quarterly earnings of 52 cents per share which beat the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $132.865 million which beat the analyst consensus estimate of $116.675 million.\nDr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”\nLiquidia shares gained 3.1% to trade at $54.80 on Tuesday.\nThese analysts made changes to their price targets on Liquidia following earnings announcement.\n\nWells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $51 to $62.\nHC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $55 to $67.\n\nConsidering buying LQDA stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635241241","isCrawlerRequest":true}